ReNeuron Group plc Logo

ReNeuron Group plc

RENE.L

(1.5)
Stock Price

3,38 GBp

-40.38% ROA

-203.52% ROE

-0.67x PER

Market Cap.

2.572.821,00 GBp

8.33% DER

0% Yield

-2037.35% NPM

ReNeuron Group plc Stock Analysis

ReNeuron Group plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ReNeuron Group plc Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.23x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (6%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

4 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

5 ROE

The stock's ROE indicates a negative return (-67.3%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-56.54%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

ReNeuron Group plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ReNeuron Group plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Sell
4 Stoch RSI Sell

ReNeuron Group plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ReNeuron Group plc Revenue
Year Revenue Growth
2002 19.000
2003 1.000 -1800%
2004 3.000 66.67%
2005 9.000 66.67%
2006 49.000 81.63%
2007 27.000 -81.48%
2008 93.000 70.97%
2009 31.000 -200%
2010 29.000 -6.9%
2011 40.000 27.5%
2012 17.000 -135.29%
2013 22.000 22.73%
2014 30.000 26.67%
2015 29.000 -3.45%
2016 46.000 36.96%
2017 43.000 -6.98%
2018 49.000 12.24%
2019 6.065.000 99.19%
2020 6.065.000 0%
2020 257.000 -2259.92%
2021 403.000 36.23%
2022 184.000 -119.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ReNeuron Group plc Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 2.395.000 100%
2005 4.333.000 44.73%
2006 4.418.000 1.92%
2007 5.166.000 14.48%
2008 3.177.000 -62.61%
2009 2.078.000 -52.89%
2010 3.763.000 44.78%
2011 4.865.000 22.65%
2012 4.786.000 -1.65%
2013 5.829.000 17.89%
2014 7.250.000 19.6%
2015 10.272.000 29.42%
2016 16.648.000 38.3%
2017 16.657.000 0.05%
2018 16.255.000 -2.47%
2019 16.335.000 0.49%
2020 16.335.000 0%
2020 6.004.000 -172.07%
2021 8.068.000 25.58%
2022 2.954.000 -173.12%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ReNeuron Group plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 987.000 100%
2005 1.608.000 38.62%
2006 1.858.000 13.46%
2007 2.059.000 9.76%
2008 1.584.000 -29.99%
2009 1.914.000 17.24%
2010 3.067.000 37.59%
2011 2.059.000 -48.96%
2012 2.319.000 11.21%
2013 2.824.000 17.88%
2014 3.693.000 23.53%
2015 4.015.000 8.02%
2016 4.139.000 3%
2017 4.616.000 10.33%
2018 4.747.000 2.76%
2019 1.914.000 -148.01%
2020 911.000 -110.1%
2020 728.000 -25.14%
2021 1.127.000 35.4%
2022 2.912.000 61.3%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ReNeuron Group plc EBITDA
Year EBITDA Growth
2002 -4.104.000
2003 -5.035.000 18.49%
2004 -3.012.000 -67.16%
2005 -5.661.000 46.79%
2006 -5.572.000 -1.6%
2007 -6.389.000 12.79%
2008 -4.447.000 -43.67%
2009 -3.759.000 -18.3%
2010 -6.483.000 42.02%
2011 -6.694.000 3.15%
2012 -6.935.000 3.48%
2013 -7.708.000 10.03%
2014 -10.269.000 24.94%
2015 -13.632.000 24.67%
2016 -19.717.000 30.86%
2017 -19.824.000 0.54%
2018 -17.697.000 -12.02%
2019 -13.504.000 -31.05%
2020 -13.404.000 -0.75%
2020 -12.590.000 -6.47%
2021 -10.706.000 -17.6%
2022 -5.508.000 -94.37%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ReNeuron Group plc Gross Profit
Year Gross Profit Growth
2002 19.000
2003 1.000 -1800%
2004 3.000 66.67%
2005 9.000 66.67%
2006 49.000 81.63%
2007 27.000 -81.48%
2008 93.000 70.97%
2009 31.000 -200%
2010 29.000 -6.9%
2011 40.000 27.5%
2012 17.000 -135.29%
2013 22.000 22.73%
2014 30.000 26.67%
2015 29.000 -3.45%
2016 46.000 36.96%
2017 43.000 -6.98%
2018 -16.196.999 100.27%
2019 -10.270.000 -57.71%
2020 6.065.000 269.33%
2020 -9.246.000 165.6%
2021 -7.665.000 -20.63%
2022 -2.770.000 -176.71%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ReNeuron Group plc Net Profit
Year Net Profit Growth
2002 -4.435.000
2003 -813.000 -445.51%
2004 -3.214.000 74.7%
2005 -6.369.000 49.54%
2006 -5.249.000 -21.34%
2007 -6.572.000 20.13%
2008 -3.667.000 -79.22%
2009 -5.850.000 37.32%
2010 -6.148.000 4.85%
2011 -6.229.000 1.3%
2012 -6.345.000 1.83%
2013 -7.066.000 10.2%
2014 -8.906.000 20.66%
2015 -11.354.000 21.56%
2016 -15.573.000 27.09%
2017 -17.615.000 11.59%
2018 -14.292.000 -23.25%
2019 -11.412.000 -25.24%
2020 -11.412.000 0%
2020 -11.347.000 -0.57%
2021 -9.689.000 -17.11%
2022 -4.464.000 -117.05%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ReNeuron Group plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 -4
2003 -1 0%
2004 -3 100%
2005 -8 71.43%
2006 -4 -75%
2007 -4 -33.33%
2008 -2 -50%
2009 -2 -100%
2010 -1 0%
2011 -1 0%
2012 -1 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 -1 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ReNeuron Group plc Free Cashflow
Year Free Cashflow Growth
2002 -3.514.000
2003 -2.818.000 -24.7%
2004 -2.813.000 -0.18%
2005 -4.758.000 40.88%
2006 -5.561.000 14.44%
2007 -6.199.000 10.29%
2008 -4.429.000 -39.96%
2009 -2.637.000 -67.96%
2010 -5.180.000 49.09%
2011 -5.816.000 10.94%
2012 -6.059.000 4.01%
2013 -6.125.000 1.08%
2014 -8.625.000 28.99%
2015 -12.213.000 29.38%
2016 -13.168.000 7.25%
2017 -15.122.000 12.92%
2018 -12.180.000 -24.15%
2019 -14.423.000 15.55%
2020 -6.077.000 -137.34%
2021 -7.713.000 21.21%
2022 -1.612.500 -378.33%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ReNeuron Group plc Operating Cashflow
Year Operating Cashflow Growth
2002 -3.281.000
2003 -2.790.000 -17.6%
2004 -2.786.000 -0.14%
2005 -4.666.000 40.29%
2006 -5.529.000 15.61%
2007 -6.079.000 9.05%
2008 -4.401.000 -38.13%
2009 -2.629.000 -67.4%
2010 -5.148.000 48.93%
2011 -5.786.000 11.03%
2012 -6.022.000 3.92%
2013 -6.004.000 -0.3%
2014 -8.245.000 27.18%
2015 -11.920.000 30.83%
2016 -12.636.000 5.67%
2017 -14.887.000 15.12%
2018 -11.992.000 -24.14%
2019 -14.304.000 16.16%
2020 -6.052.000 -136.35%
2021 -7.411.000 18.34%
2022 -1.580.500 -368.9%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ReNeuron Group plc Capital Expenditure
Year Capital Expenditure Growth
2002 233.000
2003 28.000 -732.14%
2004 27.000 -3.7%
2005 92.000 70.65%
2006 32.000 -187.5%
2007 120.000 73.33%
2008 28.000 -328.57%
2009 8.000 -250%
2010 32.000 75%
2011 30.000 -6.67%
2012 37.000 18.92%
2013 121.000 69.42%
2014 380.000 68.16%
2015 293.000 -29.69%
2016 532.000 44.92%
2017 235.000 -126.38%
2018 188.000 -25%
2019 119.000 -57.98%
2020 25.000 -376%
2021 302.000 91.72%
2022 32.000 -843.75%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ReNeuron Group plc Equity
Year Equity Growth
2002 7.196.000
2003 1.840.000 -291.09%
2004 -1.008.000 282.54%
2005 4.628.000 121.78%
2006 10.181.000 54.54%
2007 6.940.000 -46.7%
2008 3.485.000 -99.14%
2009 7.432.000 53.11%
2010 11.002.000 32.45%
2011 5.234.000 -110.2%
2012 4.908.000 -6.64%
2013 21.717.000 77.4%
2014 13.136.000 -65.32%
2015 67.658.000 80.58%
2016 53.157.000 -27.28%
2017 36.669.000 -44.96%
2018 23.417.000 -56.59%
2019 13.223.000 -77.09%
2020 18.905.000 30.06%
2021 9.888.000 -91.19%
2022 5.057.000 -95.53%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ReNeuron Group plc Assets
Year Assets Growth
2002 8.368.000
2003 2.874.000 -191.16%
2004 829.000 -246.68%
2005 5.948.000 86.06%
2006 10.996.000 45.91%
2007 7.759.000 -41.72%
2008 6.355.000 -22.09%
2009 8.123.000 21.77%
2010 12.343.000 34.19%
2011 6.762.000 -82.53%
2012 6.222.000 -8.68%
2013 24.119.000 74.2%
2014 16.087.000 -49.93%
2015 71.857.000 77.61%
2016 58.860.000 -22.08%
2017 42.618.000 -38.11%
2018 30.847.000 -38.16%
2019 20.376.000 -51.39%
2020 25.351.000 19.62%
2021 17.323.000 -46.34%
2022 9.645.000 -79.61%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ReNeuron Group plc Liabilities
Year Liabilities Growth
2002 1.172.000
2003 1.033.000 -13.46%
2004 1.837.000 43.77%
2005 1.320.000 -39.17%
2006 815.000 -61.96%
2007 819.000 0.49%
2008 2.870.000 71.46%
2009 691.000 -315.34%
2010 1.341.000 48.47%
2011 1.528.000 12.24%
2012 1.314.000 -16.29%
2013 2.402.000 45.3%
2014 2.951.000 18.6%
2015 4.199.000 29.72%
2016 5.703.000 26.37%
2017 5.949.000 4.14%
2018 7.430.000 19.93%
2019 7.153.000 -3.87%
2020 6.446.000 -10.97%
2021 7.435.000 13.3%
2022 4.588.000 -62.05%

ReNeuron Group plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.07
Price to Earning Ratio
-0.67x
Price To Sales Ratio
8.27x
POCF Ratio
-0.48
PFCF Ratio
-0.47
Price to Book Ratio
0.51
EV to Sales
-13.37
EV Over EBITDA
0.86
EV to Operating CashFlow
0.78
EV to FreeCashFlow
0.76
Earnings Yield
-1.49
FreeCashFlow Yield
-2.12
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.36
Graham NetNet
0.06

Income Statement Metrics

Net Income per Share
-0.07
Income Quality
1.39
ROE
0.08
Return On Assets
-1.18
Return On Capital Employed
-3.53
Net Income per EBT
0.84
EBT Per Ebit
0.99
Ebit per Revenue
-24.66
Effective Tax Rate
0.05

Margins

Sales, General, & Administrative to Revenue
7.46
Research & Developement to Revenue
9.55
Stock Based Compensation to Revenue
1.26
Gross Profit Margin
-1.68
Operating Profit Margin
-24.66
Pretax Profit Margin
-24.37
Net Profit Margin
-20.37

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.09
Free CashFlow per Share
-0.1
Capex to Operating CashFlow
0.03
Capex to Revenue
-0.46
Capex to Depreciation
-0.71
Return on Invested Capital
-1.01
Return on Tangible Assets
-0.4
Days Sales Outstanding
0
Days Payables Outstanding
512.11
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.71
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,14
Book Value per Share
0,09
Tangible Book Value per Share
0.09
Shareholders Equity per Share
0.09
Interest Debt per Share
0.01
Debt to Equity
0.08
Debt to Assets
0.04
Net Debt to EBITDA
1.39
Current Ratio
2.05
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.08
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ReNeuron Group plc Dividends
Year Dividends Growth

ReNeuron Group plc Profile

About ReNeuron Group plc

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

CEO
Mr. Iain Gladstone Ross B.Sc.,
Employee
26
Address
Pencoed Business Park
Pencoed, CF35 5HY

ReNeuron Group plc Executives & BODs

ReNeuron Group plc Executives & BODs
# Name Age
1 Mr. John Michael Hawkins A.C.A.
Company Secretary, Chief Financial Officer & Director
70
2 Mr. Simon Dew
Chief Business Officer
70
3 Mr. Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D
Executive Chairman
70
4 Dr. John David Sinden B.A., BA, M.A., MA, Ph.D.
Co-Founder
70
5 Ms. Suzanne Hancock
Chief Operations Officer
70
6 Dr. Randolph Corteling Ph.D.
Chief Scientific Officer
70

ReNeuron Group plc Competitors

ImmuPharma plc Logo
ImmuPharma plc

IMM.L

(0.8)
e-therapeutics plc Logo
e-therapeutics plc

ETX.L

(0.8)
Sareum Holdings plc Logo
Sareum Holdings plc

SAR.L

(0.5)
Scancell Holdings plc Logo
Scancell Holdings plc

SCLP.L

(1.0)
Oxford Biomedica plc Logo
Oxford Biomedica plc

OXB.L

(0.8)